Screen for acute arterial or venous thrombosis, bleeding, very high counts with symptoms, and features suggesting a myeloproliferative neoplasm (MPN). Most thrombocytosis is reactive.
Very high platelet counts can be associated with bleeding (acquired von Willebrand syndrome, especially above 1000–1500 × 10⁹/L) as well as thrombosis, but the count correlates poorly with thrombotic risk and does not by itself mandate emergency cytoreduction (BSH). Urgency depends on bleeding, thrombosis, neurological or visual symptoms, suspected MPN, the rate of rise and any need for urgent surgery.
Acute thrombosis with thrombocytosis may be the presenting feature of an MPN, particularly at unusual sites (splanchnic or cerebral veins). Manage the thrombosis through the relevant emergency pathway — acute venous thrombosis is anticoagulated unless contraindicated, and aspirin is not automatically added — and involve haematology if an MPN is suspected.
Erythromelalgia (red, burning extremities) is an important clue to an MPN and may respond dramatically to aspirin, but it is not diagnostic. New or severe symptoms need same-day assessment; digital ischaemia is an emergency (999).
Reactive thrombocytosis (infection, inflammation, iron deficiency, bleeding, malignancy) accounts for most cases, although proportions vary by setting. Reactive counts can exceed 700 or even 1000 × 10⁹/L, while ET may be only modestly raised — the platelet count alone cannot distinguish them.
Confirm persistent thrombocytosis and exclude transient reactive causes. A single elevated platelet count may be post-operative, post-bleeding, or post-infection.
Transient thrombocytosis is common post-infection (pneumonia, UTI), post-surgery, post-bleeding, or with active inflammation (RA flare, IBD). Recheck the FBC after the presumed cause has been treated; persistence is generally judged over at least 3 months, with longer observation for mild or variable counts (BSH 2025).
Iron deficiency is a common cause of reactive thrombocytosis. Ferritin may be falsely normal or raised in inflammation, so transferrin saturation and other iron indices help when ferritin is hard to interpret. Platelet normalisation after iron replacement is variable — recheck the FBC and iron studies rather than expecting a fixed timetable. Always check iron status in thrombocytosis.
Platelet count threshold: no single count separates reactive from clonal disease or establishes persistence. Reactive counts can exceed 700–1000 × 10⁹/L, and ET can present only modestly above 450. Persistent unexplained thrombocytosis needs evaluation even below 600, and some ET is negative for JAK2, CALR and MPL.
Blood film review can identify CML (left shift, basophilia), myelofibrosis (tear-drop cells, leucoerythroblastic picture), and ET (large abnormal platelets, megakaryocyte fragments). Essential for all persistent thrombocytosis.
Classify thrombocytosis as reactive (secondary) or clonal (primary myeloproliferative neoplasm). This determines investigation pathway and treatment urgency.
Reactive thrombocytosis is managed by treating the underlying cause; it is not usually treated with aspirin or cytoreduction, and thrombotic risk is assessed from the underlying condition rather than the platelet count. Antibiotics only for documented or strongly suspected bacterial infection; NSAIDs are not prescribed merely because the platelet count is raised.
Essential thrombocythaemia (ET) is a specialist diagnosis made after excluding reactive causes and other myeloid disorders. Thrombotic risk depends on previous thrombosis, age, JAK2 status, cardiovascular risk factors, microvascular symptoms and disease phenotype — platelet count correlates poorly with thrombotic risk (BSH) — and treatment is risk-adapted and haematology-led.
JAK2 V617F is found in most PV and in approximately 50–60% of ET; CALR and MPL frequencies vary between cohorts and diagnostic classifications. It activates JAK-STAT signalling. A positive result supports an MPN but does not by itself diagnose ET, and some ET is triple-negative.
Distinguishing ET from reactive: persistence despite treating the cause, splenomegaly, thrombosis, an abnormal film and molecular results point towards clonal disease. CRP/ESR may support an inflammatory cause, but normal inflammatory markers do not exclude reactive thrombocytosis or an MPN, and inflammation may be intermittent or occult. Iron deficiency can coexist with ET.
Examine for splenomegaly, signs of thrombosis, and microvascular symptoms suggesting myeloproliferative neoplasm.
Splenomegaly in thrombocytosis strongly suggests clonal disorder. Spleen sequestration paradoxically occurs in ET/PV despite high platelet count (extramedullary haematopoiesis). Reactive thrombocytosis does not cause splenomegaly unless the reactive cause itself does (e.g., lymphoma, infection).
Erythromelalgia (burning red extremities) is a clue to an MPN, not pathognomonic. It reflects platelet-mediated microvascular disturbance and may respond dramatically to aspirin — but aspirin is started on haematology advice after checking bleeding risk and the platelet level. New or severe symptoms need same-day assessment; digital ischaemia is an emergency (999).
Plethora and aquagenic pruritus suggest PV. Plethora reflects a raised haematocrit; aquagenic pruritus is a supportive clue for an MPN but is not diagnostic and has other dermatological and systemic causes.
Thrombotic events (stroke, MI, DVT, Budd-Chiari) can be the presenting feature of ET/PV. Unusual site thrombosis (portal, splenic, cerebral veins) is highly suggestive of JAK2+ myeloproliferative neoplasm. Screen all thrombocytosis patients for prior thrombosis.
Investigate to differentiate reactive from clonal thrombocytosis. Target investigations based on clinical context and platelet count.
JAK2 V617F testing supports an MPN when positive but does not by itself diagnose ET; diagnosis needs specialist correlation with marrow morphology and exclusion of reactive causes and other MPNs. Test persistent unexplained thrombocytosis (including below 600) via the local haematology pathway after reviewing the film, iron status and inflammatory/clinical causes.
Iron deficiency is a common cause of reactive thrombocytosis in primary care. Interpret ferritin with care in inflammation (transferrin saturation helps), treat according to the cause and local iron-replacement guidance, investigate the source of blood loss (gastrointestinal or menstrual) where appropriate, and recheck the FBC and iron studies — platelet normalisation is variable.
CRP/ESR may support an inflammatory cause, but normal inflammatory markers do not exclude reactive thrombocytosis or an MPN — inflammation may be intermittent or occult.
Bone marrow biopsy is gold standard for ET diagnosis (WHO criteria: megakaryocyte hyperplasia, no BCR-ABL, no reactive cause). Performed by haematology, not primary care. Often required, particularly if JAK2, CALR and MPL are all negative, or to exclude prefibrotic myelofibrosis (reticulin staining).
Refer on the whole clinical picture — persistence, explanation, symptoms, film, molecular results and the local pathway — not the platelet count alone. Clonal thrombocytosis requires specialist management.
Platelets ≥1000 × 10⁹/L need prompt review and haematology discussion, but not automatic emergency admission or cytoreduction: same-day specialist assessment is for symptomatic or unstable patients, bleeding, thrombosis, suspected acquired von Willebrand syndrome or suspected MPN. Platelet apheresis is a rare specialist bridge and is never indicated by the count alone.
JAK2 V617F positive supports a myeloproliferative neoplasm and warrants haematology referral. Refer urgently to haematology (NG12 has no specific platelet-count criterion for myeloproliferative neoplasms). Haematology confirms diagnosis, risk-stratifies (IPSET score for ET), and decides on aspirin ± cytoreduction.
Reactive thrombocytosis (iron deficiency, infection, inflammation) does not usually require haematology referral when a known cause adequately explains it and the count is settling with treatment. Recheck the FBC after treating the presumed cause; refer if it remains unexplained, disproportionate, progressive or accompanied by other abnormalities or symptoms.
Persistent unexplained thrombocytosis warrants haematology referral at any age, even if JAK2-negative and the count is below 700 — ET can present at any age and with only modestly raised platelets, and BSH 2025 guidance covers mutation-negative thrombocytosis.
Treatment depends on whether thrombocytosis is reactive or clonal. Reactive: treat the cause; do not routinely prescribe aspirin. Suspected or confirmed ET/PV: do not initiate aspirin or cytoreduction in primary care — management is risk-adapted, haematology-led and under a formal shared-care protocol.
ET/PV treatment options (haematology-led; GP prescribing only under the local shared-care protocol):
Next steps: see Iron deficiency anaemia · Haematological cancers · Stroke and TIA
Aspirin is commonly used in ET/PV to reduce arterial events, but its use is risk-adapted and specialist-led. It may be withheld or used cautiously with platelets >1000–1500, acquired von Willebrand syndrome, active bleeding, intolerance, CALR-mutated or very low-risk ET, concomitant anticoagulation or high GI bleeding risk.
Hydroxycarbamide (hydroxyurea) is commonly used for cytoreduction in high-risk ET. It is initiated, dosed and monitored by haematology, with formal transfer under the local shared-care protocol if GP prescribing is intended; the main toxicity is myelosuppression.
Risk stratification determines treatment and is done by haematology, considering age, previous thrombosis, JAK2 status, cardiovascular risk factors, microvascular symptoms, platelet level and acquired von Willebrand syndrome. A count above 1500 × 10⁹/L is mainly a bleeding (acquired von Willebrand) concern rather than simply a thrombotic-risk criterion.
Reactive thrombocytosis is managed by treating the underlying cause (iron, infection, inflammation); aspirin is not indicated for the platelet count itself, and any thrombotic risk is assessed according to the underlying condition rather than the count.
In ET/PV, address smoking, hypertension, diabetes, dyslipidaemia, obesity and physical inactivity through the patient's standard NICE/local cardiovascular-risk pathway; thrombocytosis does not change the usual targets.
Cardiovascular risk factors (smoking, hypertension, diabetes, dyslipidaemia, obesity, inactivity) add to thrombotic risk in ET/PV, so address them through the standard NICE/local cardiovascular-risk pathways alongside haematology-led treatment.
Smoking cessation is an important modifiable intervention because smoking adds to arterial thrombotic risk through endothelial dysfunction and platelet activation.
Hydration: dehydration raises haematocrit and blood viscosity, particularly in PV, so advise avoiding dehydration — with fluid intake adjusted for heart failure, renal impairment or prescribed fluid restriction rather than a fixed daily volume.
Immobility (long journeys, bed rest) increases venous stasis. Keep mobile; any travel or peri-operative thromboprophylaxis is based on individual VTE risk and specialist advice rather than the platelet count.
Monitor platelet trajectory, watch for thrombotic events, and re-refer if platelets rising or new symptoms. Chronic thrombocytosis requires long-term surveillance.
Platelet trajectory in reactive thrombocytosis should settle once the cause is treated. Persistence that is unexplained, disproportionate or progressive raises the possibility of clonal disease — request JAK2 per the local pathway or refer to haematology — but ongoing inflammation, infection, iron deficiency or malignancy may still explain it.
Thrombotic events on treatment indicate inadequate control. If patient has stroke/MI/DVT while on aspirin + cytoreduction, haematology escalates therapy (higher hydroxycarbamide dose, switch to anagrelide, add anticoagulation). Primary care role is early recognition and urgent referral.
Disease progression: A minority of ET evolves to myelofibrosis over time. Signs: progressive splenomegaly, tear-drop cells on film, rising LDH, transition from thrombocytosis to thrombocytopenia. Myelofibrosis requires stem cell transplant evaluation (only curative therapy).
Cardiovascular review: manage smoking, BP, lipids, diabetes, weight and activity through the patient's standard NICE/local cardiovascular-risk pathway; thrombocytosis does not change the usual targets.